Antineutrophil cytoplasmic antibody-associated vasculitis
Clinical trials for Antineutrophil cytoplasmic antibody-associated vasculitis explained in plain language.
Never miss a new study
Get alerted when new Antineutrophil cytoplasmic antibody-associated vasculitis trials appear
Sign up with your email to follow new studies for Antineutrophil cytoplasmic antibody-associated vasculitis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug avacopan under Long-Term safety review for vasculitis patients
Disease control Recruiting nowThis study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase 4 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Immune cell therapy takes on autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase 1/2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC